The Balanced Investor Club

Biotechnology Industry Analysis

669 companies analyzed • Returns from -570.4% to +505.7% • Data through Mar 19, 2026

Company List (671 Results)

View:
Sort:

Industry Performance

(669/669 companies)
2025-03-21 → 2026-03-19
Weighted Avg
+23.3%
Best
+505.7%
Worst
-570.4%
Returns Distribution
Top 5
1. SLGL+505.7%2. NKTR+446.2%3. MRSN+422.5%4. CBIO+419.5%5. SNSE+413.3%
Bottom 5
1. LEXXW-570.4%2. BCTXW-480.4%3. VINC-393.2%4. LIMN-391.6%5. KALA-333.7%

SLGL

+505.7%

Sol Gel Technologies Ltd

NKTR

+446.2%

Nektar Therapeutics

MRSN

+422.5%

Mersana Therapeutics Inc

CBIO

+419.5%

Crescent Biopharma, Inc.

SNSE

+413.3%

Sensei Biotherapeutics Inc

RAPT

+379.1%

RAPT Therapeutics Inc

LYEL

+358.1%

Lyell Immunopharma Inc

FGEN

+342.8%

FibroGen Inc

ATHA

+338.3%

Athira Pharma Inc

PMN

+334.8%

ProMIS Neurosciences Inc.

STRO

+331.6%

Sutro Biopharma

QNRX

+331.5%

Quoin Pharmaceuticals Ltd DRC

PLRZ

+318.6%

Polyrizon Ltd. Ordinary Shares

RLMD

+304.9%

Relmada Therapeutics Inc

RVMDW

+296.2%

Revolution Medicines, Inc. Warrant

NXTC

+287.3%

NextCure  Inc

ABVX

+281.4%

Abivax SA American Depositary Shares

ACXP

+275.1%

Acurx Pharmaceuticals LLC

VOR

+271.7%

Vor Biopharma Inc

PASG

+269.0%

Passage Bio Inc

1–20 of 671
Page 1 of 34
Methodology

The Weighted Average return (+23.3%) is calculated using market capitalization as weights. This gives larger companies more influence on the average, providing a more market-representative view.

622 companies with market cap data included: SLGL, NKTR, MRSN, CBIO, SNSE, RAPT, LYEL, FGEN, ATHA, PMN and 612 more...

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer